6:04 PM
 | 
Mar 06, 2013
 |  BC Extra  |  Politics & Policy

Final EMA guidelines on biosimilars for two therapeutic classes

EMA published final guidelines on Wednesday on the development of biosimilar versions of two classes of therapeutics, including guidelines on the development of multiple sclerosis (MS) drug interferon...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >